Trial Profile
A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Twice Daily Via DISKUS® Inhaler Versus Salmeterol 50mcg Twice Daily Via DISKUS® Inhaler on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 14 Oct 2008 Status changed from active, no longer recruiting to completed.
- 23 Feb 2007 New trial record.